Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALS Untangled supports further study of vinpocetine

Original source

VinpocetineALSUntangled · 29 July 2020 (opens in a new tab)

ALS Untangled reviewed vinpocetine as a possible treatment for amyotrophic lateral sclerosis (ALS). The group noted plausible mechanisms and two online reports of improved motor function while taking supplement combinations that included vinpocetine, but also noted that many people with ALS reported no benefit.

Why this matters

Vinpocetine may warrant formal research, including studies of cramps, safety, tolerability and possible effects on disease progression. The available reports do not show that vinpocetine treats ALS or changes treatment for people living with the disease.

Limitations and context

This is an expert review, not a clinical trial. The reported motor improvements came from two people using supplement cocktails, so the effect of vinpocetine cannot be separated from the other supplements. ALS Untangled said its reviewers were divided between testing vinpocetine in a preclinical ALS model and conducting a small human study. Serious side effects were described as rare, but this review did not establish effectiveness or safety in ALS.

Summarised by Compass 10 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?